By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1007 Slater Road
Suite 170
Durham  North Carolina  27703  U.S.A.
Phone: 919-328-2020 Fax: n/a


Scioderm is a biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including orphan products.

Our lead product, SD-101, is being developed for treatment of the skin effects associated with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder. There are many genetic and symptomatic variations of EB, but all share the prominent symptom of extremely fragile skin that blisters and tears from minor friction or trauma. Internal organs and bodily systems can also be seriously affected by the disease.

The skin is one of the most effective barriers in the body to prevent penetration of pharmaceuticals, which has been the primary reason for the difficulty in development of locally effective topical therapies. The key to a successful topical product is not only the active moiety but also having a formulation to effectively deliver the active ingredient across the various skin barriers. The SD-101 unique proprietary formulation has been shown to deliver the active ingredient across various skin penetration models in a dose dependent manner.

Key Statistics

Ownership: Private

Web Site: Scioderm
Employees: n/a


Company News
Amicus (FOLD) Completes Acquisition Of Scioderm 9/30/2015 7:19:57 AM
Amicus (FOLD) Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million 8/31/2015 6:37:07 AM
Scioderm To Submit Rolling NDA To U.S. FDA For Zorblisa 7/14/2015 9:27:45 AM
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa 3/19/2015 11:00:49 AM
Scioderm Appoints Ian A. W. Howes Chief Financial Officer 1/6/2015 9:38:05 AM
Scioderm To Present At 33rd Annual J.P. Morgan Healthcare Conference 1/2/2015 7:43:00 AM
Scioderm Locks In $20 Million Series B 12/18/2014 6:32:40 AM
Scioderm, Inc. To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The 13th Annual Scioderm Investor Forum 10/6/2014 7:33:23 AM
Scioderm To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The Debra International Congress 9/9/2014 8:00:41 AM
Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer 6/12/2014 7:55:17 AM